A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study

 

 Buy Article Permissions and Reprints

Summary

DZ-697b is a new orally active antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation. It does not require meta-bolisation to generate its active compound and has a safer profile than clopidogrel in pre-clinical studies. We compared the antithrombotic effects and bleeding time prolongations of three DZ-697b doses with clopidogrel 300 mg. In a four-treatment, three-period, crossover-design, 20 healthy subjects (31 ± 7 years, 85% males) were randomised to single oral doses of DZ-697b (60, 120 and 360 mg), and clopidogrel (300 mg) (n=15 in each treatment with crossing-over). Antithrombotic effects were assessed by measuring six-hour post-dose changes from baseline in thrombus size in the Badimon chamber and platelet adhesion using Diamed Impact-R platelet function assay. Bleeding times were also measured pre-dose and at six hours post-dose. DZ-697b caused dose-dependent reductions in thrombus size at both high- and low-shear rates (mean reductions at 60, 120 and 360 mg doses of: 13.0%, 18.7%, 26.4% and 11.4%, 12.7%, 22.1% respectively, p<0.05 for all). Effect of clopidogrel (reductions of 18.7% and 11.0% respectively, p<0.05 for both) was closest to DZ-697b 120 mg. Reductions in platelet adhesion were also dose-dependent. Bleeding time ratio from baseline were shorter with DZ-697b versus clopidogrel (1.3, 1.4 and 1.5 versus 1.9, p<0.05 for all). The oral agent DZ-697b shows potent, dose-dependent, antithrombotic effects that are comparable to 300 mg clopidogrel at the 120 mg dose. Despite having equal or greater anti-platelet potency than 300 mg clopidogrel, bleeding time prolongations are significantly shorter with DZ-697b.

• References

• 1 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).. CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
  CrossrefPubMedGoogle Scholar
• 2 Peters RJ, Mehta SR, Fox KA. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-1687.
  CrossrefPubMedGoogle Scholar
• 3 Yong G, Rankin J, Ferguson L. et al. Randomized trial comparing 600– with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. Am Heart J 2009; 157: 60e61-69.
  PubMedGoogle Scholar
• 4 von Beckerath N, Taubert D, Pogatsa-Murray G. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
  PubMedGoogle Scholar
• 5 Collet JP, Silvain J, Landivier A. et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 2008; 118: 1225-1233.
  CrossrefPubMedGoogle Scholar
• 6 Kastrati A, von Beckerath N, Joost A. et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-1919.
  CrossrefPubMedGoogle Scholar
• 7 L’Allier PL, Ducrocq G, Pranno N. et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 2008; 51: 1066-1072.
  CrossrefPubMedGoogle Scholar
• 8 Patti G, Colonna G, Pasceri V. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-2106.
  CrossrefPubMedGoogle Scholar
• 9 Cuisset T, Frere C, Quilici J. et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345.
  CrossrefPubMedGoogle Scholar
• 10 Paccaly A, Frick A, Ozoux ML. et al. Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 45-51.
  CrossrefPubMedGoogle Scholar
• 11 Zafar MU, Farkouh ME, Osende J. et al. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost 2007; 97: 487-492.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Zafar MU, Vorchheimer DA, Gaztanaga J. et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-888.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Buller H, Deitchman D, Prins M. et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 06: 1313-1318.
  CrossrefPubMedGoogle Scholar
• 14 Zafar MU, Vilahur G, Choi BG. et al. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost 2007; 05: 1195-1200.
  CrossrefPubMedGoogle Scholar
• 15 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
  CrossrefPubMedGoogle Scholar
• 16 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
  CrossrefPubMedGoogle Scholar
• 17 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
  CrossrefPubMedGoogle Scholar
• 18 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
  CrossrefPubMedGoogle Scholar
• 19 Erlinge D, Varenhorst C, Braun OO. et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
  CrossrefPubMedGoogle Scholar
• 20 Ogihara Y, Muramatsui S, Kanedai Y. et al. Pharmacological Profile of DZ-697b, a Novel Anti-Platelet Agent -Selective Inhibitor of vWF- and Collagen-Induced Platelet Aggregation. Blood 2005; 106: 1875.
  CrossrefPubMedGoogle Scholar
• 21 Shibutani T, Muramatsu S, Takahashi S. et al. The pharmacological profile of DZ-697b, a novel anti-platelet agent. J Thromb Haemost. 2007 5: P-M-352.
  PubMedGoogle Scholar
• 22 Shibutani T, Iijimal T, Kanedai Y. et al. Anti-Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs. Blood 2005; 106: 1870.
  PubMedGoogle Scholar
• 23 Helft G, Osende JI, Worthley SG. et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000; 20: 2316-2321.
  CrossrefPubMedGoogle Scholar
• 24 Shimbo D, Osende J, Chen J. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-738.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Osende JI, Fuster V, Lev EI. et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-1491.
  CrossrefPubMedGoogle Scholar
• 26 Dangas G, Badimon JJ, Coller BS. et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-1349.
  CrossrefPubMedGoogle Scholar
• 27 Hayes R, Chesebro JH, Fuster V. et al. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-1172.
  CrossrefPubMedGoogle Scholar
• 28 Wiviott SD, Trenk D, Frelinger AL. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
  CrossrefPubMedGoogle Scholar
• 29 Ozaki Y, Asazuma N, Suzuki-Inoue K. et al. Platelet GPIb-IX-V-dependent signaling. J Thromb Haemost 2005; 03: 1745-1751.
  CrossrefPubMedGoogle Scholar
• 30 Kasirer-Friede A, Cozzi MR, Mazzucato M. et al. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood 2004; 103: 3403-3411.
  CrossrefPubMedGoogle Scholar
• 31 Poole A, Gibbins JM, Turner M. et al. The Fc receptor gamma-chain and the tyro-sine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16: 2333-2341.
  CrossrefPubMedGoogle Scholar
• 32 Tsuji M, Ezumi Y, Arai M. et al. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997; 272: 23528-23531.
  CrossrefPubMedGoogle Scholar
• 33 Wu Y, Suzuki-Inoue K, Satoh K. et al. Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling. Blood 2001; 97: 3836-3845.
  CrossrefPubMedGoogle Scholar
• 34 Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Wille-brand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood 1999; 94: 1648-1656.
  PubMedGoogle Scholar
• 35 Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999; 25 (Suppl. 02) 3-8.
  PubMedGoogle Scholar